Erschienen in:
01.05.2013 | Editor's Invited Manuscripts - Invitation Only
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards?
A point/counterpoint discussion
verfasst von:
J. Lee Villano, Patrick Y. Wen, Eudocia Q. Lee, Lakshmi Nayak, David A. Reardon, Myrna R. Rosenfeld
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Excerpt
The observation in the early 1990’s that patients with newly diagnosed anaplastic oligodendroglioma (AO) often showed responses to the combination of procarbazine, lomustine, vincristine (PCV) led to two prospective, randomized, phase III trials aimed at evaluating the impact of neoadjuvant (RTOG 9402) or adjuvant (EORTC 26951) PCV in conjunction with standard radiation therapy (RT) for patients with newly diagnosed AO. At the time enrollment started it was unlikely that the investigators would have predicted that the story of these trials would continue to unfold over 17 years. …